185033-64-1

Upstream product

• 617-05-0 ethyl vanillate 
• 74-96-4 ethyl bromide 
• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 100-39-0 benzyl bromide 
• 121-33-5 vanillin 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 100-44-7 benzyl chloride 

Downstream Products

• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 
• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 768350-54-5 7-(benzyloxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine hydrochloride 

Relevant academic research and scientific papers

C–H-Activation approach towards the core structure of the alkaloid γ-lycorane

With a view towards the synthesis of lycorane-like structures several N-(pivaloyloxy)benzamides were reacted with cyclohexa-1,3-diene in presence of a rhodium(III) catalyst which resulted via C–H activation in the corresponding tetrahydrophenanthridinones

4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors

Erythropoietin-producing hepatocellular receptor tyrosine kinase subtype A2 (EphA2) is an attractive therapeutic target for suppressing tumor progression. In our efforts to discover novel small molecules to inhibit EphA2, a class of compound based on 4-substituted quinazoline containing 7-(morpholin-2-ylmethoxy) group was identified as a novel hit by high throughput screening campaign. Structural modification of parent quinazoline scaffolds by introducing substituents on aniline displayed potent inhibitory activities toward EphA2.

SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES

A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).

Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: 1wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4,

Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammels.

Method of lowering body temperature with (R) - 2,3-benzodiazepines

An (R)-2,3-benzodiazepine of Formula I, substantially isolated from the corresponding (S)-enantiomer thereof, is administered to lower the body temperature of an individual.

Method of lowering body temperature with (S)-2,3-benzodiazepines

An (S)-2,3-benzodiazepine of Formula I, substantially isolated from the corresponding (R)-enantiomer thereof, is administered to lower the body temperature of an individual.

Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and wherein the compound comprises the (S)-enantiomer, administered for modulation of dopamine responses and treatment of dopamine-mediated disorders.

Method of increasing neutrophil production using 2,3-benzodiazepines

Compounds according to formula I: wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered to increase neutrophil levels in mammals.

Treatment of inflammatory disorders with 2,3- benzodiazepines

Compounds according to formula I: 1 wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered for the treatment of inflammatory disorders, particularly inflammatory disorders mediated by LTB4,